Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 47.93% is 33% above its 5-year average of 36.15%, around the middle of its 5-year range (9.75%–69.39%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.52% below its 12-month average of 51.27%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 47.93%.
DEBT TO ASSETS RATIO
47.93%
DEBT TO ASSETS RATIO AVG TTM
51.27%
DEBT TO ASSETS RATIO AVG 3Y
43.72%
DEBT TO ASSETS RATIO AVG 5Y
36.15%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.52%
CURRENT VS 3Y AVG
+9.61%
CURRENT VS 5Y AVG
+32.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+53151.45%
vs the sector median at left
Humacyte, Inc.
Market Cap
$80.30M
Debt to Assets Ratio
47.93%
TTM Avg
51.27%
3Y Avg
43.72%
5Y Avg
36.15%
Market Cap
$79.61M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.03M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.59M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.29M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.47M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $80.30M | 47.93% | 51.27% | 43.72% | 36.15% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.02% | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | 0.03% | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | 0.00% | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | 0.09% | N/A | N/A | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | 0.00% | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | 0.03% | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | 0.03% | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | 0.01% | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | 0.00% | N/A | N/A | N/A |
Debt/Assets
47.9%
Debt/Equity
2.12
Current Ratio
6.21
Interest Coverage
-9.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 47.93% |
| 2026-03-31 | 59.61% |
| 2025-12-31 | 55.73% |
| 2025-09-30 | 32.59% |
| 2025-06-30 | 60.49% |
| 2025-03-31 | 9.75% |
| 2024-12-31 | 11.99% |
| 2024-09-30 | 69.39% |
| 2024-06-30 | 57.14% |
| 2024-03-31 | 47.44% |
| 2023-12-31 | 44.85% |
| 2023-09-30 | 38.01% |
| 2023-06-30 | 33.50% |
| 2023-03-31 | 27.61% |
| 2022-12-31 | 24.51% |
| 2022-09-30 | 22.50% |
| 2022-06-30 | 20.69% |
| 2022-03-31 | 19.32% |
| 2021-12-31 | 17.86% |
| 2021-09-30 | 13.91% |
| 2021-06-30 | 44.32% |
| 2021-03-31 | 40.94% |
| 2020-12-31 | 27.05% |
| 2020-09-30 | 0.09% |
| 2020-06-30 | 57.69% |
| 2019-12-31 | 17.02% |
